Your browser doesn't support javascript.
loading
Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.
Choung, Wonken; Jung, Hui Jin; Yang, Deokmo; Nam, Eun Hye; Choi, Hyukjoon; Lee, Bo Ram; Park, Min; Jang, Su Min; Lim, Jae Soo; Kim, Woo Sik; Kim, Kyung-Hee; Chin, Jungwook; Jung, Kyungjin; Lee, Geumwoo; Hong, Eunmi; Jang, Tae-Ho; Myung, Jayhyuk; Kim, Seong Heon.
Afiliação
  • Choung W; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Jung HJ; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Yang D; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Nam EH; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Choi H; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Lee BR; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Park M; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Jang SM; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Lim JS; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Kim WS; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Kim KH; New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Republic of Korea.
  • Chin J; New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Republic of Korea.
  • Jung K; New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Republic of Korea.
  • Lee G; New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Republic of Korea.
  • Hong E; New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Republic of Korea.
  • Jang TH; New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Republic of Korea.
  • Myung J; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • Kim SH; Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea. Electronic address: rose1998@boryung.co.kr.
Bioorg Med Chem Lett ; 29(4): 631-637, 2019 02 15.
Article em En | MEDLINE | ID: mdl-30594432
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Pirimidinas / Pirimidinonas / PPAR gama / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Bioorg Med Chem Lett Assunto da revista: BIOQUIMICA / QUIMICA Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Pirimidinas / Pirimidinonas / PPAR gama / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Bioorg Med Chem Lett Assunto da revista: BIOQUIMICA / QUIMICA Ano de publicação: 2019 Tipo de documento: Article